Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

26. April 2021 08:05 ET | Quelle: Facts & Factors

Global Aesthetic Lasers And Energy Devices Market Will Reach USD 3,900 Million by 2026: Facts & Factors

New York, NY, April 26, 2021 (GLOBE NEWSWIRE) -- Facts and Factors have published a new research report titled “Aesthetic Lasers And Energy Devices Market By Product Type (Body Contouring Devices,...
26. April 2021 08:00 ET | Quelle: Orasis Pharmaceuticals

Orasis Pharmaceuticals Appoints Industry Veteran, Paul Smith, as President and Chief Operating Officer to Lead the Next Phase of Growth

HERZLIYA, Israel, April 26, 2021 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing an innovative pharmaceutical solution for the...
26. April 2021 08:00 ET | Quelle: Fountain Therapeutics

Fountain Therapeutics Appoints William L. Greene, M.D. Chief Executive Officer

SOUTH SAN FRANCISCO, Calif., April 26, 2021 (GLOBE NEWSWIRE) -- Fountain Therapeutics, a biopharmaceutical company building a pipeline of therapeutics to treat age-related diseases by reversing...
23. April 2021 07:00 ET | Quelle: F. Hoffmann-La Roche Ltd

CHMP recommends EU approval of Roche’s ENSPRYNG (satralizumab) for adults and adolescents with neuromyelitis optica spectrum disorder (NMOSD)

If approved, ENSPRYNG will be the first and only treatment available to both adults and adolescents from 12 years of age with anti-aquaporin-4 antibody (AQP4-IgG) seropositive NMOSD in the EUENSPRYNG...
23. April 2021 07:00 ET | Quelle: ProQR Therapeutics N.V.

ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
23. April 2021 05:00 ET | Quelle: Aequus Pharmaceuticals

Aequus Provides General Update and Reports Record 2020 Financial Results

VANCOUVER, British Columbia, April 23, 2021 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on...
23. April 2021 01:30 ET | Quelle: NICOX

Nicox’s NCX 4251 Mississippi Phase 2b Blepharitis Trial Reaches 50% Enrollment

Press ReleaseNicox’s NCX 4251 Mississippi Phase 2b Blepharitis Trial Reaches 50% Enrollment 102 patients randomized as of April 22, 2021, out of a target of 200 Milestone shows trial remains on...
23. April 2021 01:00 ET | Quelle: F. Hoffmann-La Roche Ltd

Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy

About 90,000 women globally die from endometrial cancer each year1VENTANA MMR RxDx Panel is the first immunohistochemistry predictive test in endometrial cancer for treatment with the anti-PD1...
22. April 2021 11:36 ET | Quelle: Biosplice Therapeutics, Inc.

Biosplice Licenses Rights to Lorecivivint, a Novel Phase 3 Osteoarthritis Drug Candidate, to Samil for the Republic of Korea

SAN DIEGO, April 22, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for...
22. April 2021 08:00 ET | Quelle: Ocuphire Pharma

Ocuphire’s APX3330 for Retinal Diseases to be Presented at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting

Oral Administration of APX3330 Reduced Neovascularization in a Pre-Clinical Mouse Model of Laser-Induced Choroidal Neovascularization New Data from Physiological-Based Pharmacokinetic (PBPK) Model...

Vorherige Seite

Nächste Seite